SCHEMBL5111012

SCHEMBL5111012

COC(=O)COc1ccc(C)cc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.69
GAA P10253 1/20 0.69
L3MBTL1 Q9Y468 2/20 0.60
NPC1 O15118 1/20 0.60
TDP1 Q9NUW8 1/20 0.60
HPGD P15428 3/20 0.58
PTGS2 P35354 1/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
ALDH1A1 P00352 3/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAPT P10636 3/20 0.56
ALOX5 P09917 1/20 0.53
WDR5 P61964 1/20 0.53
HDAC1 Q13547 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2116437 0.92 PTGS2 (0.66) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL17365269 0.86 PTGS2 (0.60) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL12061812 0.86 GAA (0.66) LMNAGAAL3MBTL1NPC1HPGD
SCHEMBL197602 0.84 PTGS2 (0.58) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL7693991 0.84 PTGS2 (0.58) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL13935133 0.84 PTGS2 (0.58) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL4264046 0.84 PTGS2 (0.58) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL10364396 0.84 PTGS2 (0.58) LMNAGAAL3MBTL1PTGS2MEN1
SCHEMBL10174361 0.84 GAA (0.55) LMNAGAAL3MBTL1NPC1TDP1
SCHEMBL1107148 0.82 GAA (0.70) LMNAGAAL3MBTL1NPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-06-05 US claimed
EP-4626864-A1 LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS Protego Biopharma, Inc. (US) 2025-10-08 EP disclosed
WO-2024118801-A1 LINEAR HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS PROTEGO BIOPHARMA, INC. (US) 2024-06-06 WO disclosed
CN-117645540-A Preparation method of chlorophenoxycarboxylate 山东润博生物科技有限公司 2024-03-05 CN disclosed
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2024-01-11 US disclosed
EP-3181545-B1 PROCESS FOR THE PREPARATION OF OSPEMIFENE SHIONOGI & CO (JP) 2023-11-01 EP disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 US disclosed
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis SCRIPPS RESEARCH INST (US) 2023-03-09 US disclosed
CN-114075099-A Synthetic method of p-methyl anisole or stable isotope marker thereof 上海安谱实验科技股份有限公司 2022-02-22 CN disclosed
US-10744117-B2 PPARG modulators for the treatment of osteoporosis THE SCRIPPS RESEARCH INSTITUTE (US) 2020-08-18 US disclosed
WO-2007000550-A2 NOVEL INDOLINE COMPOUNDS LABORATOIRES FOURNIER S.A. (FR) 2007-01-04 WO disclosed
WO-2005087761-A1 NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-22 WO disclosed
CN-1008737-B Process for preparing benzo [1] oxy [5] thiacycloheptene derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1990-07-11 CN disclosed
CN-85104426-A Benzo [ 1 ] oxy [ 5 ] thiacycloheptene derivatives, their production and use 1986-04-10 CN disclosed
US-4304907-A Bicyclo lactone intermediates for prostaglandin analogs THE UPJOHN COMPANY (US) 1981-12-08 US disclosed
US-4303796-A 16-Phenoxy prostaglandin F2α analogs THE UPJOHN COMPANY (US) 1981-12-01 US disclosed
US-4116988-A 16-Phenoxy prostaglandin E1 analogs THE UPJOHN COMPANY (US) 1978-09-26 US disclosed
US-4116989-A 16-Phenoxy prostaglandin F1α analogs THE UPJOHN COMPANY (US) 1978-09-26 US disclosed
US-4087616-A 16-Phenoxy prostaglandin A2 analogs THE UPJOHN COMPANY (US) 1978-05-02 US disclosed
US-3931279-A 5-Oxa prostaglandin F2.sub.α analogs THE UPJOHN COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132496-A1 CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS F12, F11, F2 LMNA 2898/4885GAA 370/4885L3MBTL1 4590/4885
US-20230072933-A1 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885GAA 3259/4885L3MBTL1 2810/4885
US-10744117-B2 PPARG modulators for the treatment of osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885GAA 3259/4885L3MBTL1 2810/4885
US-20240009169-A9 PPARG Modulators for the Treatment of Osteoporosis PPARG, PPARA, PPARD LMNA 2029/4885GAA 3259/4885L3MBTL1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.